Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
KKR Invests In Indian Generics …
by Jean-François Tremblay
December 9, 2013
| A version of this story appeared in
Volume 91, Issue 49
The U.S. private equity firm Kohlberg Kravis Roberts will pay $200 million for a minority stake in Gland Pharma, an Indian generic drug maker. In business since 1978, Gland produces injectable drugs for sale in India, the U.S., and other countries. The company’s products include heparin and other drugs that it often ships in prefilled syringes. KKR did not disclose what percentage of Gland it is acquiring, but it is taking up the stake currently owned by Evolvence India Life Sciences Fund, another private equity investor.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter